Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Gefitinib Combined with 125I Radioactive Particles in the Treatment of Transplanted Lung Cancer Tumors in Nude Mice

  • Laboratory Investigation
  • Interventional Oncology
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Objective

To investigate the efficacy of gefitinib combined with iodine-125 (125I) radioactive particles in the treatment of transplanted tumors of the lung cancer cell line A549 in nude mice.

Materials and Methods

Twenty-four nude mice were inoculated with A549-luc human lung adenocarcinoma cells stably expressing luciferase. The tumor size was approximately 8–10 mm after 20 days. The mice were randomly divided into four groups: a control group (n = 6), an 125I particles group (n = 6), a gefitinib group (n = 6) and a gefitinib combined 125I particles implantation group (n = 6). Tumor growth was observed, and changes in tumor size were continuously measured. Bioluminescence imaging was used to detect the bioluminescence activity of human lung adenocarcinoma A549-luc cells containing the luciferase reporter gene in vivo. After 35 days, the nude mice were sacrificed, and a tumor growth curve was drawn.

Results

Before treatment, the tumor volumes of the four groups were not significantly different. The tumor volume difference was statistically significant in the four groups (control group, 125I radioactive particles, gefitinib group and combined drug group) at 5 weeks after treatment (F = 10.305, P < 0.05). The tumor size in the gefitinib combined with 125I particles group was significantly smaller than that in the gefitinib, 125I particles and control groups and significantly smaller than that before treatment. There was no significant difference in the bioluminescence signal intensity between the four groups before treatment. The numbers of biofluorescence photons difference were statistically significant in the four groups (F = 28.975, P < 0.05). The bioluminescence signal intensity in the gefitinib combined with 125I particles group was significantly lower than that in the 125I particles, gefitinib and control groups and significantly lower than that before treatment.

Conclusion

Gefitinib combined with 125I radioactive particles brachytherapy can significantly inhibit tumor growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  Google Scholar 

  3. Akhtar-Danesh N, Finley C. Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: a population-based study. Lung Cancer. 2015;90(1):8–14.

    Article  Google Scholar 

  4. He Y, Li L, Liu J, Zhang X. Iodine-125 seed brachytherapy inhibits non-small cell lung cancer by suppressing epithelial-mesenchymal transition. Brachytherapy. 2018;17(4):696–701.

    Article  Google Scholar 

  5. Zhang T, Lu M, Peng S, Zhang W, Yang G, Liu Z, Singh S, Yang Y, Zhang F, Gao F. CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol. 2014;140(8):1383–90.

    Article  CAS  Google Scholar 

  6. Li J, Yang CX, Mei ZJ, Chen J, Zhang SM, Sun SX, Zhou FX, Zhou YF, Xie CH. Involvement of cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation. Asian Pac J Cancer Prev. 2013;14(10):5725–30.

    Article  Google Scholar 

  7. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005;23(14):3227–34.

    Article  CAS  Google Scholar 

  8. Colquhoun AJ, Mellon JK. Epidermal growth factor receptor and bladder cancer. Postgrad Med J. 2002;78(924):584–9.

    Article  CAS  Google Scholar 

  9. Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, Park HC, Suh CO, Park TK, Kim BS. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer-Am. Cancer Soc. 2002;95(3):531–9.

    CAS  Google Scholar 

  10. Gotoh M, Takiuchi H, Kawabe S, Ohta S, Kii T, Kuwakado S, Katsu K. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2007;37(9):652–7.

    Article  Google Scholar 

  11. Noordhuis MG, Eijsink JJ, Ten HK, Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de Bock GH, Wisman GB, Schuuring E, van der Zee AG. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res. 2009;15(23):7389–97.

    Article  CAS  Google Scholar 

  12. Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res. 2006;12(24):7222–31.

    Article  CAS  Google Scholar 

  13. Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, Castiglia M, Rizzo S, Vullo FL, Fiorentino E, Van Meerbeeck J, Russo A. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89(2):300–13.

    Article  Google Scholar 

  14. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637–58.

    Article  CAS  Google Scholar 

  15. Luo YJ, Liu ZL, Ye PC, Fu ZM, Lu F, Suleiman AA, Liao J, Xiao JW. Safety and efficacy of intraoperative iodine-125 seed implantation brachytherapy for rectal cancer patients: a retrospective clinical research. J Gastroenterol Hepatol. 2016;31(6):1076–84.

    Article  CAS  Google Scholar 

  16. Li JR, Sun Y, Liu L. Radioactive seed implantation and lobaplatin chemotherapy are safe and effective in treating patients with advanced lung cancer. Asian Pac J Cancer Prev. 2015;16(9):4003–6.

    Article  Google Scholar 

  17. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34(34):8690–707.

    Article  CAS  Google Scholar 

  18. Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther. 2013;35(9):1282–303.

    Article  CAS  Google Scholar 

  19. Kao HF, Lin CC, Yang JC. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol. 2013;9(7):991–1003.

    Article  CAS  Google Scholar 

  20. Weber J, Haberkorn U, Mier W. Cancer stratification by molecular imaging. Int J Mol Sci. 2015;16(3):4918–46.

    Article  CAS  Google Scholar 

  21. Tung JK, Berglund K, Gutekunst CA, Hochgeschwender U, Gross RE. Bioluminescence imaging in live cells and animals. Neurophotonics. 2016;3(2):25001.

    Article  Google Scholar 

  22. Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med. 2014;3(2):172–82.

    Article  CAS  Google Scholar 

Download references

Funding

This study was supported by China Postdoctoral Research Fund (No. 2015T80489); Shanghai Municipal Health Bureau (No. 201640015); Shanghai Nature Science Foundation (19ZR1432600); Shanghai Key Specialty Construction Project (No. ZK2019A02); Shanghai Science and Technology Commission (No. 18411968600); and Shanghai Municipal Key Clinical Specialty (Nos. shslczdzk06002 and shslczdzk07002).

Author information

Author notes

  1. Chaojie Li, Linyan Yao and Ju Gong have contributed equally to this work.

Authors and Affiliations

  1. Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine, No.197, Ruijin 2nd Road, Huangpu District, Shanghai, 200020, China

    Chaojie Li, Linyan Yao, Ju Gong, Haopeng Pang, Qungang Shan, Ziyin Wang, Jian Lu & Zhongmin Wang

Authors
  1. Chaojie Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linyan Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ju Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haopeng Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qungang Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ziyin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhongmin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jian Lu or Zhongmin Wang.

Ethics declarations

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest Author contribution statement. Zhongmin Wang and Jian Lu designed the research and supervised the report. Chaojie Li, Linyan Yao and Ju Gong performed research and wrote the paper. Haopeng Pang, Qungang Shan and Ziyin Wang analyzed data. The authors declare that they have no conflict of interest. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Ethical Approval

Studies involving animal subjects Generated Statement: The animal study was reviewed and approved by Ruijin Hospital Luwan Branch Ethics Committee Shanghai Jiao Tong University School of Medicine.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, C., Yao, L., Gong, J. et al. Efficacy of Gefitinib Combined with 125I Radioactive Particles in the Treatment of Transplanted Lung Cancer Tumors in Nude Mice. Cardiovasc Intervent Radiol 43, 1364–1370 (2020). https://doi.org/10.1007/s00270-020-02550-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-020-02550-1

Keywords

Search

Navigation